Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

BACKGROUND: The efficacy and safety of rucaparib maintenance treatment in ARIEL3 were evaluated in subgroups based on best response to most recent platinum‐based chemotherapy and baseline disease. METHODS: Patients were randomized 2:1 to receive either oral rucaparib at a dosage of 600 mg twice dail...

Descripción completa

Detalles Bibliográficos
Autores principales: Oaknin, Ana, Oza, Amit M., Lorusso, Domenica, Aghajanian, Carol, Dean, Andrew, Colombo, Nicoletta, Weberpals, Johanne I., Clamp, Andrew R., Scambia, Giovanni, Leary, Alexandra, Holloway, Robert W., Amenedo Gancedo, Margarita, Fong, Peter C., Goh, Jeffrey C., O’Malley, David M., Armstrong, Deborah K., Banerjee, Susana, García‐Donas, Jesus, Swisher, Elizabeth M., Cameron, Terri, Maloney, Lara, Goble, Sandra, Ledermann, Jonathan A., Coleman, Robert L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Researcher
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525125/
https://www.ncbi.nlm.nih.gov/pubmed/34549539
http://dx.doi.org/10.1002/cam4.4260

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525125/
https://www.ncbi.nlm.nih.gov/pubmed/34549539
http://dx.doi.org/10.1002/cam4.4260

Ejemplares similares